BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vrettos EI, Mező G, Tzakos AG. On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J Org Chem 2018;14:930-54. [PMID: 29765474 DOI: 10.3762/bjoc.14.80] [Cited by in Crossref: 58] [Cited by in F6Publishing: 67] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Chis AA, Arseniu AM, Morgovan C, Dobrea CM, Frum A, Juncan AM, Butuca A, Ghibu S, Gligor FG, Rus LL. Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy. Pharmaceutics 2022;14:1773. [DOI: 10.3390/pharmaceutics14091773] [Reference Citation Analysis]
2 Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide‒drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.020] [Reference Citation Analysis]
3 Sahu BP, Baishya R, Hatiboruah JL, Laloo D, Biswas N. A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches. J Pharm Investig . [DOI: 10.1007/s40005-022-00583-x] [Reference Citation Analysis]
4 Furman O, Zaporozhets A, Tobi D, Bazylevich A, Firer MA, Patsenker L, Gellerman G, Lubin BCR. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery. Pharmaceutics 2022;14:1505. [DOI: 10.3390/pharmaceutics14071505] [Reference Citation Analysis]
5 Yang S, Banik N, Han B, Lee D, Park J. Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy. Pharmaceutics 2022;14:1378. [DOI: 10.3390/pharmaceutics14071378] [Reference Citation Analysis]
6 Bojarska J, Breza M, Remko M, Czyz M, Gajos-michniewicz A, Zimecki M, Kaczmarek K, Madura ID, Wojciechowski JM, Wolf WM. Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond. IJMS 2022;23:7173. [DOI: 10.3390/ijms23137173] [Reference Citation Analysis]
7 Tong S, Darwish S, Ariani HHN, Lozada KA, Salehi D, Cinelli MA, Silverman RB, Kaur K, Yang S. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022;14:1036. [DOI: 10.3390/pharmaceutics14051036] [Reference Citation Analysis]
8 Zhang T, Ouyang X, Gou S, Zhang Y, Yan N, Chang L, Li B, Zhang F, Liu H, Ni J. Novel Synovial Targeting Peptide-Sinomenine Conjugates as a Potential Strategy for the Treatment of Rheumatoid Arthritis. Int J Pharm 2022;:121628. [PMID: 35245636 DOI: 10.1016/j.ijpharm.2022.121628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Xu L, Xu S, Xiang T, Liu H, Chen L, Jiang B, Yao J, Zhu H, Hu R, Chen Z. Multifunctional building elements for the construction of peptide drug conjugates. Engineered Regeneration 2022. [DOI: 10.1016/j.engreg.2022.02.004] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Wang L, Chen H, Wang F, Zhang X. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv 2022. [PMID: 35130795 DOI: 10.1080/17425247.2022.2039621] [Reference Citation Analysis]
11 Yang B, Wang T, Yang Y, Zhu H, Li J. The application progress of peptides in drug delivery systems in the past decade. Journal of Drug Delivery Science and Technology 2021;66:102880. [DOI: 10.1016/j.jddst.2021.102880] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pokharel M, Park K. Light mediated drug delivery systems: a review. J Drug Target 2021;:1-13. [PMID: 34761711 DOI: 10.1080/1061186X.2021.2005610] [Reference Citation Analysis]
13 Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, Malkas LH. Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells 2021;10:2908. [PMID: 34831131 DOI: 10.3390/cells10112908] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
14 Guo XM, Yadav MB, Khan M, Hao CW, Lin CY, Huang T, Wu J, Fan BM, Bian ZX. Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer. J Med Chem 2021. [PMID: 34699215 DOI: 10.1021/acs.jmedchem.1c00705] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Wang MD, Hou DY, Lv GT, Li RX, Hu XJ, Wang ZJ, Zhang NY, Yi L, Xu WH, Wang H. Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency. Biomaterials 2021;278:121139. [PMID: 34624753 DOI: 10.1016/j.biomaterials.2021.121139] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
16 Aslam B, Arshad MI, Aslam MA, Muzammil S, Siddique AB, Yasmeen N, Khurshid M, Rasool M, Ahmad M, Rasool MH, Fahim M, Hussain R, Xia X, Baloch Z. Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics. Infect Dis Ther 2021;10:1171-93. [PMID: 34170506 DOI: 10.1007/s40121-021-00446-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Tubío-Santamaría N, Ebstein F, Heidel FH, Krüger E. Immunoproteasome Function in Normal and Malignant Hematopoiesis. Cells 2021;10:1577. [PMID: 34206607 DOI: 10.3390/cells10071577] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
18 Cooper BM, Iegre J, O' Donovan DH, Ölwegård Halvarsson M, Spring DR. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem Soc Rev 2021;50:1480-94. [PMID: 33346298 DOI: 10.1039/d0cs00556h] [Cited by in Crossref: 10] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
19 Saghaeidehkordi A, Chen S, Yang S, Kaur K. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. Pharmaceutics 2021;13:661. [PMID: 34063098 DOI: 10.3390/pharmaceutics13050661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Yang DC, Chen CH. Potential New Therapeutic Approaches for Renal Cell Carcinoma. Semin Nephrol 2020;40:86-97. [PMID: 32130970 DOI: 10.1016/j.semnephrol.2019.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
21 Qu Y, Wang H, Liu H, Sun X, Li J, Yu H. Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer. Biomed Res Int 2021;2021:8811751. [PMID: 33987445 DOI: 10.1155/2021/8811751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Baranyai Z, Biri-Kovács B, Krátký M, Szeder B, Debreczeni ML, Budai J, Kovács B, Horváth L, Pári E, Németh Z, Cervenak L, Zsila F, Méhes E, Kiss É, Vinšová J, Bősze S. Cellular Internalization and Inhibition Capacity of New Anti-Glioma Peptide Conjugates: Physicochemical Characterization and Evaluation on Various Monolayer- and 3D-Spheroid-Based in Vitro Platforms. J Med Chem 2021;64:2982-3005. [PMID: 33719423 DOI: 10.1021/acs.jmedchem.0c01399] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
23 Gayraud F, Klußmann M, Neundorf I. Recent Advances and Trends in Chemical CPP-Drug Conjugation Techniques. Molecules 2021;26:1591. [PMID: 33805680 DOI: 10.3390/molecules26061591] [Reference Citation Analysis]
24 Borbély A, Pethő L, Szabó I, Al-Majidi M, Steckel A, Nagy T, Kéki S, Kalló G, Csősz É, Mező G, Schlosser G. Structural Characterization of Daunomycin-Peptide Conjugates by Various Tandem Mass Spectrometric Techniques. Int J Mol Sci 2021;22:1648. [PMID: 33562082 DOI: 10.3390/ijms22041648] [Reference Citation Analysis]
25 Lee J, Kim C. Peptide Materials for Smart Therapeutic Applications. Macromol Res 2021;29:2-14. [DOI: 10.1007/s13233-021-9011-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Balogh B, Ivánczi M, Nizami B, Beke-Somfai T, Mándity IM. ConjuPepDB: a database of peptide-drug conjugates. Nucleic Acids Res 2021;49:D1102-12. [PMID: 33125057 DOI: 10.1093/nar/gkaa950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhou X, Smith QR, Liu X. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1695. [PMID: 33470550 DOI: 10.1002/wnan.1695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
28 Cirillo M, Giacomini D. Molecular Delivery of Cytotoxic Agents via Integrin Activation. Cancers (Basel) 2021;13:299. [PMID: 33467465 DOI: 10.3390/cancers13020299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kougioumtzi A, Chatziathanasiadou MV, Vrettos EI, Sayyad N, Sakka M, Stathopoulos P, Mantzaris MD, Ganai AM, Karpoormath R, Vartholomatos G, Tsikaris V, Lazarides T, Murphy C, Tzakos AG. Development of novel GnRH and Tat48-60 based luminescent probes with enhanced cellular uptake and bioimaging profile. Dalton Trans 2021;50:9215-24. [PMID: 34125130 DOI: 10.1039/d1dt00060h] [Reference Citation Analysis]
30 Alas M, Saghaeidehkordi A, Kaur K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem 2021;64:216-32. [PMID: 33382619 DOI: 10.1021/acs.jmedchem.0c01530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
31 Wu Y, Williams J, Calder EDD, Walport LJ. Strategies to expand peptide functionality through hybridisation with a small molecule component. RSC Chem Biol 2021;2:151-65. [PMID: 34458778 DOI: 10.1039/d0cb00167h] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Vrettos EI, Karampelas T, Sayyad N, Kougioumtzi A, Syed N, Crook T, Murphy C, Tamvakopoulos C, Tzakos AG. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer. Eur J Med Chem 2021;211:113018. [PMID: 33223264 DOI: 10.1016/j.ejmech.2020.113018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Schmelcher M, Loessner MJ. Bacteriophage endolysins - extending their application to tissues and the bloodstream. Curr Opin Biotechnol 2021;68:51-9. [PMID: 33126104 DOI: 10.1016/j.copbio.2020.09.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
34 Thakor P, Bhavana V, Sharma R, Srivastava S, Singh SB, Mehra NK. Polymer–drug conjugates: recent advances and future perspectives. Drug Discovery Today 2020;25:1718-26. [DOI: 10.1016/j.drudis.2020.06.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Das R, Gayakvad B, Shinde SD, Rani J, Jain A, Sahu B. Ultrashort Peptides—A Glimpse into the Structural Modifications and Their Applications as Biomaterials. ACS Appl Bio Mater 2020;3:5474-99. [DOI: 10.1021/acsabm.0c00544] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
36 Khaledian M, Nourbakhsh MS, Saber R, Hashemzadeh H, Darvishi MH. Preparation and Evaluation of Doxorubicin-Loaded PLA-PEG-FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy. Int J Nanomedicine 2020;15:6167-82. [PMID: 32922000 DOI: 10.2147/IJN.S261638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
37 Ma Y, Mou Q, Yan D, Zhu X. Engineering small molecule nanodrugs to overcome barriers for cancer therapy. View 2020;1:20200062. [DOI: 10.1002/viw.20200062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
38 Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020;8:571. [PMID: 32733853 DOI: 10.3389/fchem.2020.00571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
39 Ueno S, Kim MW, Lee G, Park YI, Niidome T, Lee R. Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer. Pharmaceutics 2020;12:E585. [PMID: 32599712 DOI: 10.3390/pharmaceutics12060585] [Reference Citation Analysis]
40 Dókus LE, Lajkó E, Ranđelović I, Mező D, Schlosser G, Kőhidai L, Tóvári J, Mező G. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer. Pharmaceutics 2020;12:E576. [PMID: 32580307 DOI: 10.3390/pharmaceutics12060576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
41 Gupta S, Singh I, Sharma AK, Kumar P. Ultrashort Peptide Self-Assembly: Front-Runners to Transport Drug and Gene Cargos. Front Bioeng Biotechnol 2020;8:504. [PMID: 32548101 DOI: 10.3389/fbioe.2020.00504] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
42 Panda PK, Saraf S, Tiwari A, Verma A, Raikwar S, Jain A, Jain SK. Novel Strategies for Targeting Prostate Cancer. Curr Drug Deliv 2019;16:712-27. [PMID: 31433757 DOI: 10.2174/1567201816666190821143805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
43 Worm DJ, Els‐heindl S, Beck‐sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Peptide Science 2020;112. [DOI: 10.1002/pep2.24171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
44 Shah SS, Casanova N, Antuono G, Sabatino D. Polyamide Backbone Modified Cell Targeting and Penetrating Peptides in Cancer Detection and Treatment. Front Chem 2020;8:218. [PMID: 32296681 DOI: 10.3389/fchem.2020.00218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Hayat F, Migaud ME. Nicotinamide riboside-amino acid conjugates that are stable to purine nucleoside phosphorylase. Org Biomol Chem 2020;18:2877-85. [PMID: 32236231 DOI: 10.1039/d0ob00134a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Perini MV, Dmello RS, Nero TL, Chand AL. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther 2020;211:107527. [PMID: 32173557 DOI: 10.1016/j.pharmthera.2020.107527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
47 Rajavenkatesh K, Padmaja M, Janani I, Aishwarya S, Purna Sai K, Thennarasu S. Design and synthesis of a novel peptide for selective detection of cancer cells. Chem Biol Drug Des 2020;95:610-23. [PMID: 32147880 DOI: 10.1111/cbdd.13675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Poreba M. Protease-activated prodrugs: strategies, challenges, and future directions. FEBS J 2020;287:1936-69. [PMID: 31991521 DOI: 10.1111/febs.15227] [Cited by in Crossref: 15] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
49 Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat 2020;50:100682. [PMID: 32087558 DOI: 10.1016/j.drup.2020.100682] [Cited by in Crossref: 37] [Cited by in F6Publishing: 74] [Article Influence: 18.5] [Reference Citation Analysis]
50 Ailuno G, Baldassari S, Zuccari G, Schlich M, Caviglioli G. Peptide-based nanosystems for vascular cell adhesion molecule-1 targeting: a real opportunity for therapeutic and diagnostic agents in inflammation associated disorders. Journal of Drug Delivery Science and Technology 2020;55:101461. [DOI: 10.1016/j.jddst.2019.101461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Piorecka K, Smith D, Kurjata J, Stanczyk M, Stanczyk WA. Synthetic routes to nanoconjugates of anthracyclines. Bioorg Chem 2020;96:103617. [PMID: 32014639 DOI: 10.1016/j.bioorg.2020.103617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
52 Noisier AFM, Johansson MJ, Knerr L, Hayes MA, Drury WJ, Valeur E, Malins LR, Gopalakrishnan R. Late‐Stage Functionalization of Histidine in Unprotected Peptides. Angew Chem Int Ed 2019;58:19096-102. [DOI: 10.1002/anie.201910888] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
53 Ziaei E, Saghaeidehkordi A, Dill C, Maslennikov I, Chen S, Kaur K. Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates. Bioconjug Chem 2019;30:3098-106. [PMID: 31715102 DOI: 10.1021/acs.bioconjchem.9b00755] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
54 Ranđelović I, Schuster S, Kapuvári B, Fossati G, Steinkühler C, Mező G, Tóvári J. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice. Int J Mol Sci 2019;20:E4763. [PMID: 31557968 DOI: 10.3390/ijms20194763] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
55 Sarhadi S, Ganjali S, Pirro M, Sahebkar A. The role of high-density lipoproteins in antitumor drug delivery. IUBMB Life 2019;71:1442-52. [PMID: 31290612 DOI: 10.1002/iub.2105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Feni L, Parente S, Robert C, Gazzola S, Arosio D, Piarulli U, Neundorf I. Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide. Bioconjug Chem 2019;30:2011-22. [PMID: 31243977 DOI: 10.1021/acs.bioconjchem.9b00292] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
57 Liu Y, Ding W, Ge H, Ponnusamy M, Wang Q, Hao X, Wu W, Zhang Y, Yu W, Ao X, Wang J. FOXK transcription factors: Regulation and critical role in cancer. Cancer Lett 2019;458:1-12. [PMID: 31132431 DOI: 10.1016/j.canlet.2019.05.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
58 Jafari B, Pourseif MM, Barar J, Rafi MA, Omidi Y. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery 2019;16:583-605. [DOI: 10.1080/17425247.2019.1614911] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
59 Pettenuzzo N, Brustolin L, Coltri E, Gambalunga A, Chiara F, Trevisan A, Biondi B, Nardon C, Fregona D. CuII and AuIII Complexes with Glycoconjugated Dithiocarbamato Ligands for Potential Applications in Targeted Chemotherapy. ChemMedChem 2019;14:1162-72. [PMID: 31091012 DOI: 10.1002/cmdc.201900226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
60 Dharmatti R, Miyatake H, Nandakumar A, Ueda M, Kobayashi K, Kiga D, Yamamura M, Ito Y. Enhancement of Binding Affinity of Folate to Its Receptor by Peptide Conjugation. Int J Mol Sci 2019;20:E2152. [PMID: 31052315 DOI: 10.3390/ijms20092152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
61 Borbély A, Figueras E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, Frese M, Gallinari P, Steinkühler C, Sewald N. Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery. Pharmaceutics 2019;11:E151. [PMID: 30939768 DOI: 10.3390/pharmaceutics11040151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
62 Sayyad N, Vrettos EI, Karampelas T, Chatzigiannis CM, Spyridaki K, Liapakis G, Tamvakopoulos C, Tzakos AG. Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile. European Journal of Medicinal Chemistry 2019;166:256-66. [DOI: 10.1016/j.ejmech.2019.01.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
63 White BH, Whalen K, Kriksciukaite K, Alargova R, Au Yeung T, Bazinet P, Brockman A, DuPont M, Oller H, Lemelin CA, Lim Soo P, Moreau B, Perino S, Quinn JM, Sharma G, Shinde R, Sweryda-Krawiec B, Wooster R, Bilodeau MT. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo. J Med Chem 2019;62:2708-19. [PMID: 30735385 DOI: 10.1021/acs.jmedchem.8b02036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
64 Rozovsky A, Ebaston TM, Zaporozhets A, Bazylevich A, Tuchinsky H, Patsenker L, Gellerman G. Theranostic system for ratiometric fluorescence monitoring of peptide-guided targeted drug delivery. RSC Adv 2019;9:32656-64. [DOI: 10.1039/c9ra06334j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
65 Bumbaca B, Li Z, Shah DK. Pharmacokinetics of protein and peptide conjugates. Drug Metab Pharmacokinet 2019;34:42-54. [PMID: 30573392 DOI: 10.1016/j.dmpk.2018.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
66 Chen R, Wang J, Qian C, Ji Y, Zhu C, Wu L, Li W, Bi X, Wang Y, Cao G, Chen Z. From Nanofibers to Nanorods: Nanostructure of Peptide-Drug Conjugates Regulated by Polypeptide-PEG Derivative and Enhanced Antitumor Effect. Adv Funct Mater 2019;29:1806058. [DOI: 10.1002/adfm.201806058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
67 El Mubarak MA, Leontari I, Efstathia G, Vrettos EI, Shaikh AK, Konstantinos SE, Danika C, Kalofonos HP, Tzakos AG, Sivolapenko GB. Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings. Journal of Chromatography B 2018;1092:515-23. [DOI: 10.1016/j.jchromb.2018.05.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]